Clovis Oncology Inc (CLVS) 52.76 $CLVS
Technical Updates on Biotech Stocks -- Research on Alexion Pharma, Acorda Therapeutics, Clovis Oncology, and Sangamo BioSciences
PR Newswire - Fri May 09, 11:30AM CDT
The markets on Thursday, May 08, 2014 ended on a mixed note as the S&P 500 finished the session 0.14% lower at 1,875.63, and the NASDAQ Composite closed at 4,051.50, down 0.40%. The Dow Jones Industrial Average finished at 16,550.97, up 0.20%. During the session, the five out of ten sectors ended in positive. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 1.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Acorda Therapeutics Inc. (NASDAQ: ACOR), Clovis Oncology Inc. (NASDAQ: CLVS) and Sangamo BioSciences Inc. (NASDAQ: SGMO). Free technical research on ALXN, ACOR, CLVS and SGMO can be downloaded upon signing up at:
Clovis Oncology Announces First Quarter 2014 Operating Results
Business Wire - Thu May 08, 3:03PM CDT
--CO-1686 Phase 2 expansion cohorts enrolling
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Epizyme Nominates Dr. Andrew R. Allen For Election to Board of Directors
PR Newswire - Wed Apr 30, 4:24PM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew R. Allen, M.D., Ph.D., co-founder and Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer of Clovis Oncology, Inc., has been nominated for election to the company's board of directors. The election of directors will take place at the company's annual meeting, scheduled for June 9, 2014.
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 28, 4:02PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
Clovis Oncology to Announce First Quarter 2014 Financial Results and Host Webcast Conference Call on May 8
Business Wire - Mon Apr 28, 3:05PM CDT
Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its first quarter 2014 financial results on Thursday, May 8, 2014, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast on Thursday, May 8, at 4:30 p.m. ET to discuss the company's results in greater detail.
Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 23 Drug Profiles
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rx8bp/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Eli Lilly and Company - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Deciphera Pharmaceuticals, LLC - Xcovery, Inc. - AB Science - Clovis Oncology, Inc. - EirGen Pharma Ltd. - AROG Pharmaceuticals LLC Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - olaratumab - linsitinib - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib - luminespib - MEK-162 - TH-302 - buparlisib hydrochloride - CS-2164 - Mixed Bacterial Vaccine - X-82 - quizartinib - DCC-2618 - Mutant cKIT Inhibitor - Drug Targeting c-Kit - Eir-108 For more information visit http://www.researchandmarkets.com/research/8r...intestinal
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals finally had some luck with a troubled program. Clovis Oncology took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Citigroup and GameStop are big market movers
AP - Thu Mar 27, 3:40PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
4 Stocks Triggering Breakouts on Unusual Volume
at The Street - Thu Mar 27, 8:15AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Morning Movers in Biotech: Clovis Oncology, Inc., Exact Sciences Corporation, GlaxoSmithKline PLC, a
George Budwell, The Motley Fool - Motley Fool - Thu Mar 27, 8:00AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Clovis Oncology's CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1 Study Results in Patients with Non-small Cell Lung Cancer (NSCLC)
Business Wire - Thu Mar 27, 4:00AM CDT
--PFS greater than six months in heavily-pretreated T790M+ patient population; median not yet reached
Better Buy: Clovis Oncology, Inc. or Endocyte, Inc?
George Budwell, The Motley Fool - Motley Fool - Mon Mar 24, 5:00PM CDT
Biotechs developing treatments for diseases with few therapeutic options can perform well in a variety of situations. This is especially true for developmental stage oncology companies because of the strong demand for new treatments. Indeed, ...
'Fast Money' Recap: China Syndrome
at The Street - Thu Mar 06, 4:00AM CST
The trading panel discussed how to invest in and around China.
Why Clovis Oncology, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:21PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Clovis Oncology , a clinical-stage...
Wood Resources International LLC: China imported logs and lumber for a record nine billion dollars in 2013, with North America, Russia and New Zealand being the major suppliers
Business Wire - Fri Feb 28, 2:45AM CST
Importation of logs and lumber to China reached a new record in 2013 with lumber imports being up 19% and log imports increasing 23% from 2012, as reported in the Wood Resource Quarterly. North America, Russia and New Zealand were the major supplying countries but Sweden, Finland, Ukraine, Chile and Australia saw the biggest increases in market share
Technical Updates on Biotech Stocks -- Research on Alexion Pharma, Acorda Therapeutics, Clovis Oncology, and Sangamo BioSciences
PR Newswire - Fri May 09, 11:30AM CDT
The markets on Thursday, May 08, 2014 ended on a mixed note as the S&P 500 finished the session 0.14% lower at 1,875.63, and the NASDAQ Composite closed at 4,051.50, down 0.40%. The Dow Jones Industrial Average finished at 16,550.97, up 0.20%. During the session, the five out of ten sectors ended in positive. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 1.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Acorda Therapeutics Inc. (NASDAQ: ACOR), Clovis Oncology Inc. (NASDAQ: CLVS) and Sangamo BioSciences Inc. (NASDAQ: SGMO). Free technical research on ALXN, ACOR, CLVS and SGMO can be downloaded upon signing up at:
Clovis Oncology Announces First Quarter 2014 Operating Results
Business Wire - Thu May 08, 3:03PM CDT
--CO-1686 Phase 2 expansion cohorts enrolling
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Epizyme Nominates Dr. Andrew R. Allen For Election to Board of Directors
PR Newswire - Wed Apr 30, 4:24PM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew R. Allen, M.D., Ph.D., co-founder and Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer of Clovis Oncology, Inc., has been nominated for election to the company's board of directors. The election of directors will take place at the company's annual meeting, scheduled for June 9, 2014.
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 28, 4:02PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
Clovis Oncology to Announce First Quarter 2014 Financial Results and Host Webcast Conference Call on May 8
Business Wire - Mon Apr 28, 3:05PM CDT
Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its first quarter 2014 financial results on Thursday, May 8, 2014, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast on Thursday, May 8, at 4:30 p.m. ET to discuss the company's results in greater detail.
Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 23 Drug Profiles
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rx8bp/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Eli Lilly and Company - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Deciphera Pharmaceuticals, LLC - Xcovery, Inc. - AB Science - Clovis Oncology, Inc. - EirGen Pharma Ltd. - AROG Pharmaceuticals LLC Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - olaratumab - linsitinib - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib - luminespib - MEK-162 - TH-302 - buparlisib hydrochloride - CS-2164 - Mixed Bacterial Vaccine - X-82 - quizartinib - DCC-2618 - Mutant cKIT Inhibitor - Drug Targeting c-Kit - Eir-108 For more information visit http://www.researchandmarkets.com/research/8r...intestinal
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals finally had some luck with a troubled program. Clovis Oncology took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Citigroup and GameStop are big market movers
AP - Thu Mar 27, 3:40PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
4 Stocks Triggering Breakouts on Unusual Volume
at The Street - Thu Mar 27, 8:15AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Morning Movers in Biotech: Clovis Oncology, Inc., Exact Sciences Corporation, GlaxoSmithKline PLC, a
George Budwell, The Motley Fool - Motley Fool - Thu Mar 27, 8:00AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Clovis Oncology's CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1 Study Results in Patients with Non-small Cell Lung Cancer (NSCLC)
Business Wire - Thu Mar 27, 4:00AM CDT
--PFS greater than six months in heavily-pretreated T790M+ patient population; median not yet reached
Better Buy: Clovis Oncology, Inc. or Endocyte, Inc?
George Budwell, The Motley Fool - Motley Fool - Mon Mar 24, 5:00PM CDT
Biotechs developing treatments for diseases with few therapeutic options can perform well in a variety of situations. This is especially true for developmental stage oncology companies because of the strong demand for new treatments. Indeed, ...
'Fast Money' Recap: China Syndrome
at The Street - Thu Mar 06, 4:00AM CST
The trading panel discussed how to invest in and around China.
Why Clovis Oncology, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:21PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Clovis Oncology , a clinical-stage...
Wood Resources International LLC: China imported logs and lumber for a record nine billion dollars in 2013, with North America, Russia and New Zealand being the major suppliers
Business Wire - Fri Feb 28, 2:45AM CST
Importation of logs and lumber to China reached a new record in 2013 with lumber imports being up 19% and log imports increasing 23% from 2012, as reported in the Wood Resource Quarterly. North America, Russia and New Zealand were the major supplying countries but Sweden, Finland, Ukraine, Chile and Australia saw the biggest increases in market share
